- Home
- ANAB vs SCSC Comparison
ANAB vs SCSC Comparison
Compare ANAB & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- SCSC
- Stock Information
- Founded
- ANAB 2005
- SCSC 1992
- Country
- ANAB United States
- SCSC United States
- Employees
- ANAB N/A
- SCSC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- SCSC Retail: Computer Software & Peripheral Equipment
- Sector
- ANAB Health Care
- SCSC Technology
- Exchange
- ANAB Nasdaq
- SCSC Nasdaq
- Market Cap
- ANAB 759.5M
- SCSC 892.1M
- IPO Year
- ANAB 2017
- SCSC 1994
- Fundamental
- Price
- ANAB $18.59
- SCSC $37.20
- Analyst Decision
- ANAB Buy
- SCSC Hold
- Analyst Count
- ANAB 12
- SCSC 1
- Target Price
- ANAB $41.20
- SCSC N/A
- AVG Volume (30 Days)
- ANAB 1.4M
- SCSC 236.7K
- Earning Date
- ANAB 03-10-2025
- SCSC 01-30-2025
- Dividend Yield
- ANAB N/A
- SCSC N/A
- EPS Growth
- ANAB N/A
- SCSC N/A
- EPS
- ANAB N/A
- SCSC 2.54
- Revenue
- ANAB $57,172,000.00
- SCSC $3,021,788,000.00
- Revenue This Year
- ANAB $229.13
- SCSC N/A
- Revenue Next Year
- ANAB N/A
- SCSC $6.58
- P/E Ratio
- ANAB N/A
- SCSC $14.67
- Revenue Growth
- ANAB 282.17
- SCSC N/A
- 52 Week Low
- ANAB $12.21
- SCSC $36.63
- 52 Week High
- ANAB $41.31
- SCSC $53.90
- Technical
- Relative Strength Index (RSI)
- ANAB 55.28
- SCSC 25.01
- Support Level
- ANAB $12.21
- SCSC $36.71
- Resistance Level
- ANAB $21.57
- SCSC $37.81
- Average True Range (ATR)
- ANAB 1.72
- SCSC 1.17
- MACD
- ANAB 0.39
- SCSC -0.07
- Stochastic Oscillator
- ANAB 68.16
- SCSC 12.45
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.